Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMT-009 in advanced solid tumors and lymphomas
NCT05565417Phase 2Active, not recruiting
- Sponsor
- Immunitas Therapeutics
- Start
- Nov 2022
- Primary completion
- Jan 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IMT-009 in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), cutaneous squamous cell carcinoma (cSCC), hormone receptor-positive breast cancer, sponsored by Immunitas Therapeutics. Started Nov 2022; status: active, not recruiting.
02
Drugs
IMT-009
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)triple-negative breast cancer (TNBC)cutaneous squamous cell carcinoma (cSCC)hormone receptor-positive breast cancer
Beyond the preview
Go deeper on NCT05565417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05565417.